Cognition Therapeutics Inc (CGTX)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$0.72+2.60%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Cognition Therapeutics Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.137
Annual ending 2026-12-31
Revenue	—	18.3M
EPS	—	-0.297
Annual ending 2027-12-31
Revenue	—	41.93M
EPS	—	-0.22

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain sufficient cash to fund operations through Q2 2027	It has enough cash to operate through Q2 2027.	Intact	Cash falls short of funding operations through Q2 2027	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Reduce operating losses toward sustainable levels	Operating losses improved from $13.7M to $8.8M.	Broken	Operating loss worsens beyond negative $8.8M next quarter	Operating income: $-7.738M FY2026-Q2; GAAP. Published target: Operating loss improves to better than negative $8.8M per quarter. The target does not explicitly identify fiscal versus calendar quarters. Source published Aug 7, 2026-7,738,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 90a55512-42e5-460e-a42a-b40e3686b969. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Advance toward regulatory approval for Dementia with Lewy Bodies (DLB)	A supporting condition in Cognition Therapeutics Inc's published investment case. The stated target is Progress to registrational trial or regulatory approval for DLB.	Improving	No progress or setbacks in DLB regulatory pathway within 12 months	Qualitative progress: 2 positive regulatory/funding events (Jun 2026, May 2026) vs 12-month target News confirms movement closer to registrational trial for DLB and receipt of donation to extend the program. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	3 / 3
2026-07-25	Unavailable	Unavailable	3 / 3
2026-07-26	Unavailable	Unavailable	3 / 3
2026-07-27	Unavailable	Unavailable	3 / 3
2026-07-28	Unavailable	Unavailable	3 / 3
2026-07-29	Unavailable	Unavailable	3 / 3
2026-07-30	Unavailable	Unavailable	3 / 3
2026-07-31	Unavailable	Unavailable	3 / 2
2026-08-01	Unavailable	Unavailable	3 / 3
2026-08-02	Unavailable	Unavailable	2 / 2
2026-08-03	Unavailable	Unavailable	2 / 2
2026-08-04	Unavailable	Unavailable	2 / 2
2026-08-05	Unavailable	Unavailable	2 / 2
2026-08-06	Unavailable	Unavailable	2 / 2
2026-08-07	Unavailable	Unavailable	2 / 1
2026-08-08	Unavailable	Unavailable	2 / 2
2026-08-09	Unavailable	Unavailable	2 / 2
2026-08-10	Unavailable	Unavailable	2 / 1
2026-08-11	Unavailable	Unavailable	2 / 1
2026-08-12	Unavailable	Unavailable	2 / 1
2026-08-13	Unavailable	Unavailable	2 / 2
2026-08-14	Unavailable	Unavailable	2 / 1
2026-08-15	Unavailable	Unavailable	2 / 1
2026-08-16	Unavailable	Unavailable	2 / 1
2026-08-17	Unavailable	Unavailable	2 / 1
2026-08-18	Unavailable	Unavailable	2 / 1
2026-08-19	Unavailable	Unavailable	2 / 1
2026-08-20	Unavailable	Unavailable	2 / 1
2026-08-21	Unavailable	Unavailable	2 / 1
2026-08-22	Unavailable	Unavailable	2 / 1
2026-08-23	Unavailable	Unavailable	2 / 1
2026-08-24	Unavailable	Unavailable	2 / 1
2026-08-25	Unavailable	Unavailable	2 / 1
2026-08-26	Unavailable	Unavailable	2 / 1
2026-08-27	Unavailable	Unavailable	2 / 1
2026-08-28	Unavailable	Unavailable	2 / 1
2026-08-29	Unavailable	Unavailable	2 / 1
2026-08-30	Unavailable	Unavailable	2 / 1
2026-08-31	Unavailable	Unavailable	2 / 1
2026-09-01	Unavailable	Unavailable	2 / 1
2026-09-02	Unavailable	Unavailable	2 / 1
2026-09-03	Unavailable	Unavailable	2 / 1
2026-09-04	Unavailable	Unavailable	2 / 1
2026-09-05	Unavailable	Unavailable	2 / 1
2026-09-06	Unavailable	Unavailable	2 / 1
2026-09-07	Unavailable	Unavailable	2 / 1
2026-09-08	Unavailable	Unavailable	2 / 1
2026-09-09	Unavailable	Unavailable	2 / 1
2026-09-10	Unavailable	Unavailable	2 / 1
2026-09-11	Unavailable	Unavailable	2 / 1
2026-09-12	Unavailable	Unavailable	2 / 1
2026-09-13	Unavailable	Unavailable	2 / 1
2026-09-14	Unavailable	Unavailable	2 / 1
2026-09-15	Unavailable	Unavailable	2 / 1
2026-09-16	Unavailable	Unavailable	2 / 1
2026-09-17	Unavailable	Unavailable	2 / 1
2026-09-18	Unavailable	Unavailable	2 / 1
2026-09-19	Unavailable	Unavailable	2 / 1
2026-09-20	Unavailable	Unavailable	2 / 1
2026-09-21	Unavailable	Unavailable	2 / 1
2026-09-22	Unavailable	Unavailable	2 / 1
2026-09-23	Unavailable	Unavailable	2 / 1
2026-09-24	Unavailable	Unavailable	2 / 1
2026-09-25	Unavailable	Unavailable	2 / 1
2026-09-26	Unavailable	Unavailable	2 / 1
2026-09-27	Unavailable	Unavailable	2 / 1
2026-09-28	Unavailable	Unavailable	2 / 1
2026-09-29	Unavailable	Unavailable	2 / 1
2026-09-30	Unavailable	Unavailable	2 / 1
2026-10-01	Unavailable	Unavailable	2 / 1
2026-10-02	Unavailable	Unavailable	2 / 1
2026-10-03	Unavailable	Unavailable	2 / 1
2026-10-04	Unavailable	Unavailable	2 / 1
2026-10-05	Unavailable	Unavailable	2 / 1
2026-10-06	Unavailable	Unavailable	2 / 1
2026-10-07	Unavailable	Unavailable	2 / 1
2026-10-08	Unavailable	Unavailable	2 / 1
2026-10-09	Unavailable	Unavailable	2 / 1
2026-10-10	Unavailable	Unavailable	2 / 1
2026-10-11	Unavailable	Unavailable	2 / 1
2026-10-12	Unavailable	Unavailable	2 / 1
2026-10-13	Unavailable	Unavailable	2 / 1
2026-10-14	Unavailable	Unavailable	2 / 1
2026-10-15	Unavailable	Unavailable	2 / 1
2026-10-16	Unavailable	Unavailable	2 / 1
2026-10-17	Unavailable	Unavailable	2 / 1
2026-10-18	Unavailable	Unavailable	2 / 1
2026-10-19	Unavailable	Unavailable	2 / 1
2026-10-20	Unavailable	Unavailable	2 / 1
2026-10-21	Unavailable	Unavailable	2 / 1
2026-10-22	Unavailable	Unavailable	2 / 1
2026-10-23	Unavailable	Unavailable	2 / 1
2026-10-24	Unavailable	Unavailable	2 / 1

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	4	0	0
2026-06-01	4	0	0
2026-07-01	4	0	0
2026-08-01	3	0	0
2026-09-01	3	0	0
2026-10-01	3	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 3 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain sufficient cash to fund operations through Q2 2027Direct metric needs a verified mapping
Reduce operating losses toward sustainable levelsPublished status: Broken

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.1%Typical daily move · historical

Downside history

-67.0%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Cognition Therapeutics Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is speculative clinical-stage growth, not an established earnings compounder. The 1-to-3-year thesis remains in a watch state: management has made regulatory and planning progress, but the evidence does not yet establish trial execution or clinical results.

What's priced into Cognition Therapeutics Inc

The evidence snapshot provides no valuation or market-expectations data, so whether the shares are cheap or expensive versus peers, or what expectations are already reflected, cannot be assessed. The business is loss-making, and confidence in the evidence is low.

What the fundamentals likely do

Near term, the company remains loss-making, although reported operating expenses were lower year over year in the first and second quarters of 2026. Cash and management's stated runway improved, with the stated runway moving to the fourth quarter of 2027, but this does not establish trial delivery. Recent earnings beats are positive context, while the risk label has risen to high and the company remains worth watching into its next financial update.

What Cognition Therapeutics Inc hinges on

Over the multi-year view, the thesis hinges on advancing zervimesine into a registrational DLB trial and generating evidence from the START study; the supplied evidence shows planning and regulatory progress, not trial outcomes. Near term, a guidance cut is a stated negative trigger, while continued strength among healthcare bellwethers is a potential sector tailwind. Weaker jobs data could raise recession concerns, and the snapshot gives limited evidence on how that would affect this company specifically.